Abbreviations used in this issue ANA = antinuclear antibody CIN3+ = cervical intraepithelial neoplasia grade 3 or worse CMR = cardiovascular magnetic resonance HPV = human papillomavirus LGE = late gadolinium enhancement LGV = lymphogranuloma venereum MI = myocardial infarction NT-proBNP = amino-terminal pro-brain natriuretic peptide PCR = polymerase chain reaction TTF1 = thyroid transcription factor 1 Sense what can't be seen.
Sense what can't be seen.
The Aptima Trichomonas vaginalis assay is the first nucleic acid amplification test (NAAT) to test both symptomatic and asymptomatic patients -delivering up to 100% sensitivity, detecting infections missed by traditional methods and improving patients' care. 
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Summary:
Mycoplasma genitalium infection is associated with non-gonococcal urethritis in men, especially nonchlamydial non-gonococcal urethritis (accounting for 10-35% of cases), and cervicitis and pelvic inflammatory disease in women. Diagnosis is achieved with nucleic acid amplification testing, which is indicated in the presence of symptoms or high-risk sexual behaviour (asymptomatic infections are frequent). Following diagnosis, an assay for macrolide resistance should be performed, if available. Detection of M. genitalium and recent sexual contact (previous 3 months) with an infected individual are indications for treatment. In macrolide susceptible infections, azithromycin achieves a cure rate of 85-95% compared with 30-40% with doxycycline, although the latter does not increase resistance. Widespread use of azithromycin 1 g single dose without test of cure is the most likely cause of drastically declining overall cure rates due to macrolide resistance (an extended course appears to have a higher cure rate). For uncomplicated macrolide susceptible M. genitalium infection, the recommended first-line treatment is oral azithromycin 500 mg on day 1, then 250 mg on days 2-5, or oral josamycin 500 mg three times daily for 10 days. Moxifloxacin 400 mg once daily for 7-10 days can be used as second-line treatment or in macrolide resistant infection. Third-line treatment options include doxycycline 100 mg two times daily for 14 days or oral pristinamycin 1 g four times daily for 10 days. The recommended treatment of complicated M. genitalium infection (pelvic inflammatory disease, epididymitis) is moxifloxacin 400 mg once daily for 14 days.
Comment: Firstly, my congratulations to Dr Massimo Giola from BOP DHB who gave a very elegant presentation on these important new guidelines at the recent NZ Sexual and Reproductive Health and Rights conference held in Wellington, timed brilliantly for just before the November earthquake swarm kicked off. As he pointed out, the unassuming M. genitalium has barely made it onto the healthcare radar in NZ but it threatens to take the prize for the most antibiotic resistant genitourinary pathogen in the country. This is a problem since we have only patchy availability of nucleic acid amplification testing for M. genitalium and no routine availability of macrolide susceptibility genotyping indicated by this guideline. However, I have recently successfully trialled the SpeeDx Mycoplasma genitalium Resistance Plus kit which genotypes mutations in the 23SrRNA gene associated with resistance to macrolides, and I believe that Canterbury Health Laboratories are now offering this assay. Unfortunately though, moxifloxacin, the recommended alternative therapy to azithromycin, is also losing its efficacy with many strains acquiring the gyrA mutation associated with quinolone resistance. 
Abstract
Could molecular pathology testing in lung cancer be more cost-effective?
Authors: Walsh K, et al.
Summary:
In order to explore different strategies that might reduce laboratory service costs associated with non-small cell lung carcinoma, data from an audit of molecular pathology testing in the South East Scotland Cancer Network was analysed, including an assessment of thyroid transcription factor 1 (TTF1) expression as a negative predictor for EGFR mutations. TTF1 immunohistochemistry demonstrated a 99% negative predictive value for EGFR mutations. Compared with reflex testing of all non-squamous non-small cell lung carcinoma for EGFR and ALK mutations, a 7.5% reduction in costs could be achieved by limiting testing to only those who might be considered for targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors or anaplastic lymphoma kinase (ALK) inhibitors. However, with a serial testing model based on the mutually exclusive relationship between EGFR, KRAS and ALK mutations, a 32.7% reduction in costs was possible. If TTF1 is validated as a negative predictive biomarker, further savings could be made (total cost reduction of 37.5%).
Comment: The existence of this paper is reflective of both the expensive nature of molecular oncology testing and the fact that most clinical laboratories are experiencing increasing pressures to reduce costs. This clinical audit of lung cancer pathology requests trialled four models of testing algorithms and found the most cost saving approach was to test all non-small cell lung carcinoma patients with immunohistochemistry for TTF1 and ALK rearrangements, where only TTF1-positive, ALK-negative samples would have KRAS mutation analysis and then only those with no KRAS mutations would be tested for EGFR mutations. The disadvantages include an extended turnaround time compared with reflex testing, and the risk of exhausting the sample when specimen size and thus DNA yield is limiting. Although promising, there is too little data on the association between TTF1 immunohistochemistry and EGFR to fully support its use as a negative predictor for EGFR mutations. As ever, further work is needed.
Reference: J Clin Pathol. 2016 Oct;69(10):938-41. Abstract
Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands Authors: Dijkstra MG, et al.
Summary:
In the population-based POBASCAM trial in the Netherlands, 43,339 women aged 29-61 years with a negative human papillomavirus (HPV) and/or negative cervical cytology test were randomised to HPV and cytology co-testing (intervention) or cytology testing only (control) comprising of three screening rounds, one every 5 years. The cumulative incidences of cervical cancer and cervical intraepithelial neoplasia grade 3 or worse (CIN3+) were similar among HPV-negative women in the intervention group after three rounds of screening (0.09% and 0.56%, respectively) and among women with negative cytology in the control group after two rounds (0.09% and 0.69%, respectively). Risk ratios for cervical cancer and CIN3+ were not significant. In HPV-negative women, CIN3+ incidence was 72.2% lower among those aged 40 years or more versus younger women (p<0.001). No significant association between cervical cancer incidence and age was reported. Among HPV-positive women with negative cytology, HPV 16/18 genotyping, and/or repeat cytology, CIN3+ incidence was 10.4 times higher than among HPV-negative women. The authors concluded that these long-term data support an extension of the cervical screening interval beyond five years for women aged 40 years and older.
Comment: I couldn't let an issue of the Review go past without including a paper on cervical screening and HPV testing! This study reports on a 14-year long follow-up of the large Dutch POBASCAM study, which compared HPV and cytology co-testing with cytology only, and used 5 yearly screening intervals. The study findings support what is already known about the long-term protective effect of a HPV-negative test, and the limited value of primary HPV and cytology co-testing. Additionally, the data confirms that in women at least 40 years old, a 10-year screening interval confers good safety for both cervical cancer and CIN3+. This is pretty good news for women in the Netherlands, who in 2017 will move to an HPV primary screening programme with exactly these 10-year intervals for 40+ women. This approach is termed "risk-based screening" and is not being considered in Australia or New Zealand, with both following the Netherlands into the land of HPV primary screening in 2017 and 2018, respectively, but with 5-year intervals over all age ranges. Whew. 
CLICK HERE
FOR MORE INFORMATION
Laboratory Medicine Research Review a publication
Chromosome microarray proficiency testing and analysis of quality metric data trends through an external quality assessment program for Australasian laboratories Authors: Wright DC, et al.
Summary: Quality control metrics are needed to minimise false-positive and falsenegative results of chromosome microarrays for investigating chromosome and gene copy number mutations. The authors of this study reported on an external chromosome microarray proficiency testing programme for Australasian laboratories that evaluated analytical accuracy, result interpretation, report completeness, and laboratory performance data. Between 2009 and 2014, nine proficiency test samples with data from up to 23 laboratories demonstrated 30-100% analytical accuracy, 32-96% correct interpretation and 30-92% report completeness. Between 2007 and 2014, laboratory performance metrics indicated an overall mean success rate of 99.2% and abnormality rate of 23.6%. During this period, reporting times decreased from >90 days to <30 days for normal results and from >102 days to <35 days for abnormal results. Data trends showed a significant positive correlation for report completeness and reporting times. It remains unclear whether overall improvement in laboratory performance was a result of participation in the programme or from increasing laboratory experience over time.
Comment:
The need for external quality assurance was underlined in this study by the initially alarming data from the pilot in 2009 where only three out of 10 laboratories correctly identified and reported a male with no abnormality. However, interpretation performance improved over time, but considerable variability persisted in report completion, with data such as sample identifiers and date received, microarray design and genome build often left incomplete. Median reporting times have improved for both normal and abnormal results. There was a steady increase in the number of laboratories and the number of microarray tests, reflecting the growth of molecular genetics in diagnostic pathology overall. The migration of what was originally a research tool into the clinical laboratory has been technically challenging and has necessitated the establishment of quality control metrics for many aspects of laboratory practice associated with chromosome microarray testing and analysis. Conceptually, this has been the case for a number of molecular and genetic technologies and will continue to be so, especially given the increasing diagnostic utility of Next Generation Sequencing for both genetic and infectious diseases.
Reference: Pathology. 2016 Oct; 48(6):586-96 . Abstract
Lymphogranuloma venereum presenting with erythema nodosum
Authors: Borsje A, et al. LGV presenting with erythema nodosum. He reported that he was in a heterosexual relationship and denied having sex with men. His prior medical history was unremarkable. The authors proposed that this case highlights the need to consider a diagnosis of LGV outside of the usual context.
Comment: You may know that C. trachomatis is one of my very favourite bugs…It comes in a number of different colours and flavours and despite being supposedly genetically static, continues to enthral us with new and unexpected manifestations. One of these is anorectal LGV in men who have sex with men, which has been found sporadically in New Zealand. However, this paper describes an inguinal presentation of LGV in a heterosexual man with painful erythema nodosum on his lower legs as the primary complaint. It is clinically interesting because 1) it shows spread of LGV to the heterosexual community, and 2) by the secondary stage of the disease, the C. trachomatis DNA is no longer detectable in the urine, only in the fluid from the abscess. Comment: Hyperferritinaemia is a common finding and it can be difficult to determine if the raised level is due to iron overload or whether it is part of the acute-phase response in infective or inflammatory processes. Indeed, increased serum ferritin is found in 30% of individuals with non-alcoholic fatty liver disease and goes up with body mass index. These more common conditions appear to escape the attention of many general practitioners who reflexively request expensive genotyping of the HFE gene for hereditary haemochromatosis on every patient with a raised serum ferritin. In fact, a raised transferrin saturation (>45%) is the stronger predictor for iron overload due to hereditary haemochromatosis. This paper could serve as a useful handout for labs to provide as part of demand management for both HFE genotyping and repeated serum ferritin tests.
Reference: Eur J Intern Med. 2016 Sep; 33:21-7 . Abstract A novel and practical screening tool for the detection of silent myocardial infarction in patients with type 2 diabetes Authors: Swoboda PP, et al.
Summary: Silent myocardial infarction (MI) is a common occurrence in type 2 diabetes patients. The most validated technique to investigate silent MI is late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR). Since this method is time-consuming, costly, and requires administration of intravenous contrast, the authors of this study aimed to develop a low-cost population screening tool to identify type 2 diabetes patients at highest risk of silent MI, validated against the CMR reference standard. Electrocardiogram, echocardiography, biomarker assessment, and CMR at 3.0T were performed on 100 asymptomatic type 2 diabetes patients with no history of cardiovascular disease. Global longitudinal strain from two-and four-chamber cines was measured using feature tracking. Silent MI was detected in 17 patients by LGE on CMR, only four of which had Q waves on electrocardiogram. Older age (65 vs 60, p=0.05), lower E/A ratio (0.75 vs 0.89, p=0.004), lower global longitudinal strain (-15.2% vs -17.7%, p=0.004) , and higher amino-terminal pro brain natriuretic peptide (NT-proBNP) (106 ng/L vs 52 ng/L, p=0.003) were significantly associated with silent MI. A risk score combining these four factors had an area under the receiver operating characteristic curve of 0.823 (0.734-0.892), p<0.0001. For a score >3/5, sensitivity for silent MI was 82% and specificity 72%.
Comment: This is the first study to assess silent MI by LGE CMR in a truly asymptomatic diabetic population. Alarmingly, it showed the rate was higher than expected at 17%, which makes this a timely study in validating an alternative screening tool to expensive LGE CMR. Of the blood tests applied, only NT-proBNP showed a significant elevation in those with silent MI. There was no difference in high-sensitivity C-reactive protein or high-sensitivity cardiac troponin T. When NT-proBNP was combined with E/A value and global longitudinal strain measurement from echocardiography as well as patient age, an accurate risk score can be calculated with alternative cut-offs depending on the clinical need for specificity over sensitivity. Either scenario was superior to screening using Q waves, which had a sensitivity of only 24% in this asymptomatic cohort. Sounds promising, but with a low proportion of women in their cohort and the exclusion of higher-risk patients, the general applicability of the findings is uncertain.
Reference: J Clin Endocrinol Metab. 2016 Sep; 101(9):3316-23 . Abstract
